<DOC>
	<DOC>NCT02074657</DOC>
	<brief_summary>To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with relapsed or refractary acute leukemia</brief_summary>
	<brief_title>"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1. Patients between 0 and 23 years of age with diagnosis of acute lymphoblastic leukemia, in second relapse situation, posttransplant relapse or refractary, or 2. Patients between 0 and 23 years of age with diagnosis of acute myeloblastic leukemia, relapsed or refractary. (Patient must meet inclusion criteria 1 or 2) 3. Lansky index &gt; 60% 4. Mild (&lt;2) functional organs alteration (hepatic, renal, respiratory) according to National Cancer Institute criteria (NCI CTCAE v4). 5. Left ventricular ejection fraction &gt; 39% 6. To grant informed consent in accordance with the current legal regulations. 7. Presence of a compatible haploidentical donor (father or mother or brother). 1. Patients with history of bad therapeutical compliance 2. Patients not valid after psychosocial evaluation 3. Positive HIV serology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>NKAEs</keyword>
	<keyword>Expanded haploidentical natural killer cells</keyword>
	<keyword>Activated natural killer cells</keyword>
</DOC>